Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141180 · ClinicalTrials.gov registry record · Phase 1
CP-481,715 Nickel Allergy Study.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00141180: Completed Phase 1 study, sponsored by Pfizer.
NCT00141180 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141180, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
Interventions
- DRUG CP-481,715
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2003-09 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
What the finished NCT00141180 record still lists
NCT00141180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 1 intervention - of which CP-481,715 is the first listed.
NCT00141180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00141180 about?
NCT00141180 is a clinical study titled "CP-481,715 Nickel Allergy Study.". To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
What is the current status of trial NCT00141180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2003-09. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00141180?
The interventions under investigation include: CP-481,715 (DRUG).
Who is sponsoring clinical trial NCT00141180?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00141180's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia